SCHEDULE 13G: Commodore Capital Discloses 5.3% Passive Stake in Viridian Therapeutics

Commodore Capital LP and Commodore Capital Master LP have jointly disclosed a passive beneficial ownership of 5.3% in Viridian Therapeutics, Inc., totaling 4.3 million shares.

Summary

• Commodore Capital LP and Commodore Capital Master LP (collectively, "Commodore Capital") have filed a Schedule 13G, reporting beneficial ownership in Viridian Therapeutics, Inc.
• As of April 4, 2025, Commodore Capital beneficially owns an aggregate of 4,300,000 shares of Viridian Therapeutics' common stock.
• This ownership represents 5.3% of the Issuer's outstanding common stock.
• The calculation is based on 81,484,950 shares of common stock reported as issued and outstanding by Viridian Therapeutics, Inc. as of February 20, 2025, in its Annual Report on Form 10-K filed on March 3, 2025.
• Commodore Capital LP, a Delaware limited partnership, acts as the investment manager to Commodore Capital Master LP, a Cayman Islands exempted limited partnership.
• Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a Schedule 13G is a routine disclosure, the emergence of a new significant passive investor can be interpreted as a vote of confidence in the company's value, without implying any immediate operational changes or activist intentions.

Positives

• The disclosure of a significant 5.3% stake by an investment firm like Commodore Capital can signal confidence in Viridian Therapeutics' future prospects and valuation.
• The passive nature of the investment, as certified by the filers, suggests a long-term investment horizon rather than an activist intent, which can be viewed positively by the market.

Risks

• The filing itself does not detail specific risks related to Viridian Therapeutics' operations or financial health, as it is a beneficial ownership report.
• General market risks and risks inherent to the biotechnology industry (e.g., clinical trial outcomes, regulatory approvals, competition) remain relevant for Viridian Therapeutics, though not explicitly discussed in this filing.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or strategic plans.

Industry Context

The filing indicates an investment firm's significant stake in a biotechnology company, a common occurrence in the sector where specialized funds often take positions in companies with promising pipelines or technologies. Such investments can provide capital stability and market validation.

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor may influence investor sentiment and potentially the stock price, signaling institutional interest.
• Company Management: Awareness of a new 5%+ shareholder, even if passive, may be noted by management, though it does not imply immediate operational changes.

Next Steps

• Commodore Capital will be required to file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by 1% or more) or if their investment intent changes from passive to active.

Key Dates

Keywords

Viridian Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Firm, Biotechnology, SEC Filing, Passive Investment